182 related articles for article (PubMed ID: 38092485)
21. Targeted therapy paves the way for the cure of acute lymphoblastic leukaemia.
Rafei H; Kantarjian HM; Jabbour EJ
Br J Haematol; 2020 Jan; 188(2):207-223. PubMed ID: 31566728
[TBL] [Abstract][Full Text] [Related]
22. Tyrosine kinase inhibitors in Ph+ acute lymphoblastic leukaemia: facts and perspectives.
Malagola M; Papayannidis C; Baccarani M
Ann Hematol; 2016 Apr; 95(5):681-93. PubMed ID: 26891878
[TBL] [Abstract][Full Text] [Related]
23. The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades.
Jabbour E; Short NJ; Jain N; Haddad FG; Welch MA; Ravandi F; Kantarjian H
J Hematol Oncol; 2023 Mar; 16(1):22. PubMed ID: 36927623
[TBL] [Abstract][Full Text] [Related]
24. Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia.
Harrison CJ
Br J Haematol; 2009 Jan; 144(2):147-56. PubMed ID: 19006567
[TBL] [Abstract][Full Text] [Related]
25. Genomics in acute lymphoblastic leukaemia: insights and treatment implications.
Roberts KG; Mullighan CG
Nat Rev Clin Oncol; 2015 Jun; 12(6):344-57. PubMed ID: 25781572
[TBL] [Abstract][Full Text] [Related]
26. The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report.
De Benedittis C; Papayannidis C; Venturi C; Abbenante MC; Paolini S; Parisi S; Sartor C; Cavo M; Martinelli G; Soverini S
BMC Cancer; 2017 Aug; 17(1):523. PubMed ID: 28779753
[TBL] [Abstract][Full Text] [Related]
27. Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia.
Jabbour E; Pui CH; Kantarjian H
JAMA Oncol; 2018 Oct; 4(10):1413-1420. PubMed ID: 29931220
[TBL] [Abstract][Full Text] [Related]
28. Treatment of Older Patients with Acute Lymphoblastic Leukaemia.
Gökbuget N
Drugs Aging; 2018 Jan; 35(1):11-26. PubMed ID: 29256044
[TBL] [Abstract][Full Text] [Related]
29. Emerging BCR/ABL1 Mutations Under Treatment with Tyrosine Kinase Inhibitors in Paediatric Acute Lymphoblastic Leukaemia.
Molinos-Quintana A; Aquino V; Montero I; Pérez-de Soto C; García-Lozano R; Pérez-Simón JA; Pérez-Hurtado JM
Acta Haematol; 2015; 134(2):71-5. PubMed ID: 25895602
[TBL] [Abstract][Full Text] [Related]
30. Defining low-risk high hyperdiploidy in patients with paediatric acute lymphoblastic leukaemia: a retrospective analysis of data from the UKALL97/99 and UKALL2003 clinical trials.
Enshaei A; Vora A; Harrison CJ; Moppett J; Moorman AV
Lancet Haematol; 2021 Nov; 8(11):e828-e839. PubMed ID: 34715050
[TBL] [Abstract][Full Text] [Related]
31. Targeting signaling pathways in acute lymphoblastic leukemia: new insights.
Harrison CJ
Hematology Am Soc Hematol Educ Program; 2013; 2013():118-25. PubMed ID: 24319172
[TBL] [Abstract][Full Text] [Related]
32. Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia.
Boer JM; Steeghs EM; Marchante JR; Boeree A; Beaudoin JJ; Beverloo HB; Kuiper RP; Escherich G; van der Velden VH; van der Schoot CE; de Groot-Kruseman HA; Pieters R; den Boer ML
Oncotarget; 2017 Jan; 8(3):4618-4628. PubMed ID: 27894077
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapy in leukaemia.
Mu X; Chen C; Dong L; Kang Z; Sun Z; Chen X; Zheng J; Zhang Y
Acta Biochim Biophys Sin (Shanghai); 2023 Jun; 55(6):974-987. PubMed ID: 37272727
[TBL] [Abstract][Full Text] [Related]
34. BCR/ABL1-like acute lymphoblastic leukemia: How to diagnose and treat?
Chiaretti S; Messina M; Foà R
Cancer; 2019 Jan; 125(2):194-204. PubMed ID: 30561755
[TBL] [Abstract][Full Text] [Related]
35. Targeted Therapy in the Treatment of Pediatric Acute Lymphoblastic Leukemia-Therapy and Toxicity Mechanisms.
Lejman M; Kuśmierczuk K; Bednarz K; Ostapińska K; Zawitkowska J
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575992
[TBL] [Abstract][Full Text] [Related]
36. BCR/ABL1-Like Acute Lymphoblastic Leukemia: From Diagnostic Approaches to Molecularly Targeted Therapy.
Płotka A; Lewandowski K
Acta Haematol; 2022; 145(2):122-131. PubMed ID: 34818644
[TBL] [Abstract][Full Text] [Related]
37. Evidence-based review of genomic aberrations in B-lymphoblastic leukemia/lymphoma: Report from the cancer genomics consortium working group for lymphoblastic leukemia.
Akkari YMN; Bruyere H; Hagelstrom RT; Kanagal-Shamanna R; Liu J; Luo M; Mikhail FM; Pitel BA; Raca G; Shago M; Shao L; Smith LR; Smolarek TA; Yenamandra A; Baughn LB
Cancer Genet; 2020 May; 243():52-72. PubMed ID: 32302940
[TBL] [Abstract][Full Text] [Related]
38. Cytogenetics in the management of children and adult acute lymphoblastic leukemia (ALL): an update by the Groupe francophone de cytogénétique hématologique (GFCH).
Baranger L; Cuccuini W; Lefebvre C; Luquet I; Perot C; Radford I; Lafage-Pochitaloff M
Ann Biol Clin (Paris); 2016 Oct; 74(5):547-560. PubMed ID: 27707671
[TBL] [Abstract][Full Text] [Related]
39. Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease.
Roberts KG; Pei D; Campana D; Payne-Turner D; Li Y; Cheng C; Sandlund JT; Jeha S; Easton J; Becksfort J; Zhang J; Coustan-Smith E; Raimondi SC; Leung WH; Relling MV; Evans WE; Downing JR; Mullighan CG; Pui CH
J Clin Oncol; 2014 Sep; 32(27):3012-20. PubMed ID: 25049327
[TBL] [Abstract][Full Text] [Related]
40. Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial.
Marks DI; Kirkwood AA; Rowntree CJ; Aguiar M; Bailey KE; Beaton B; Cahalin P; Castleton AZ; Clifton-Hadley L; Copland M; Goldstone AH; Kelly R; Lawrie E; Lee S; McMillan AK; McMullin MF; Menne TF; Mitchell RJ; Moorman AV; Patel B; Patrick P; Smith P; Taussig D; Yallop D; Alapi KZ; Fielding AK
Lancet Haematol; 2022 Apr; 9(4):e262-e275. PubMed ID: 35358441
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
